Key Highlights
- First-half Revenue rose 53% to £2.06m and gross Margin widened to 60.4% from 55%.
- Operating profit of £79,000 replaced a £153,000 loss, with profit for the period of £86,000.
- Cash closed at £1.244m, barely changed from £1.266m, with no financing activity in the half.
- One customer accounted for £1.014m, or 49.2%, of first-half revenue.
ProBiotix Health plc (AQSE:PBX) has just done something few microcap life-sciences companies manage: it reported a profit. Unaudited interim results published on 6 August 2026 showed revenue for the six months to 30 June 2026 up 53% to £2.06m, a half-year profit before tax of £79,000 and a gross margin above 60%, all without raising fresh money. The Aquis-quoted business, which develops the patented cholesterol-lowering probiotic strain LPLDL, is now telling shareholders it is "fully funded" for its expansion plans.
The question is whether that shift from loss to profit is durable. The board argued in March that its fundamentals were "not yet fully reflected" in its market value, yet a single customer supplied almost half of first-half revenue.
Interim results: first-half profit as revenue climbs 53%
The 6 August 2026 interim statement is the key recent development. Revenue rose to £2.06m from £1.34m in the first half of 2025, Gross Profit climbed 66% to £1.245m and gross margin widened to 60.4% from 55%. EBITDA, excluding share-based payments, swung to a £151,000 profit from a £112,000 loss, and operating profit was £79,000 against a £153,000 loss. Profit for the period was £86,000, or 0.05p per share, compared with a loss of 0.09p per share in H1 2025.
Operating cash outflow narrowed to just £19,000 from £347,000, and with no financing activity the cash balance closed at £1.244m, barely changed from £1.266m at the end of 2025. Management said the balance is "sufficient to deliver our expansion ambitions and leaves the Group fully funded".
The active customer base grew by more than 15% in the half, five new partnerships were signed and existing customers expanded, most notably in China through the Kemin distribution partnership. A clinical study of LPLDL in prediabetes and diabetes is now recruiting. Chief executive Steen Andersen described progress as "pleasing" and pointed to "further growth in H2 from APAC and the EMEA regions", with 2027 expansion driven by third-party distribution and positioning LPLDL "beyond cholesterol health".
On 26 May 2026 the company announced an exclusive alliance with Spanish nutraceutical firm Bioksan, which is reformulating its Lipok cardiovascular product to replace red yeast rice with LPLDL in Spain and Portugal, projected to generate around €200,000 of annual sales for ProBiotix. Agreements followed in Slovakia (1 June) and Belgium, where Nutrisan will sell LPLDL capsules to pharmacists (23 July).
What ProBiotix Health does
ProBiotix Health was spun out of OptiBiotix Health plc, which remains a major shareholder, and describes itself as a life sciences Business developing probiotics for cardiometabolic health. Its core asset is LPLDL, a patented probiotic strain backed by peer-reviewed clinical evidence for supporting healthy cholesterol metabolism through the gut microbiome.
Revenue comes from supplying LPLDL as an ingredient to supplement brands and from finished products such as CholBiome and the menopause-focused YourBiotixMH range, sold directly or through territorial distributors. The United States is the largest market, contributing £1.048m of first-half 2026 revenue, up from £760,000. China delivered £276,000 (H1 2025: £51,000) as the Kemin Partnership gained traction, and the rest of the world contributed £735,000, up from £499,000. UK sales were nil. The shares are quoted on the Aquis Stock Exchange, where the company moved from the Access to the Apex segment on 10 November 2025.
Financial track record: from losses to breakeven
Audited results for the year to 31 December 2025, published on 30 March 2026, showed revenue up 45% to £2.73m from £1.88m and gross profit up 46% to £1.48m, with gross margin edging up to 54%. The EBITDA loss from continuing operations, before share-based payments, narrowed by 34% to £426,000, although the reported operating loss widened to £1.235m from £852,000 because of a £753,000 share-based payment charge; the basic loss per share was 0.78p (2024: 0.63p). Year-end cash was £1.27m, down from £1.65m, with no debt. With roughly 158m shares in issue, the 31 December 2025 share price of 7.75p implied a Market Capitalisation of about £12m.
The FY25 statement also disclosed a profitable first quarter of 2026, a record order book of £1.3m, up 110%, and a customer portfolio that had grown by about 50% to 23. No Dividend has been paid and the company has not issued formal Earnings guidance.
What could drive the stock next?
The board has guided to further second-half growth from Asia-Pacific and EMEA, so a Q3 trading update in the autumn will show whether momentum has held. Full-year 2026 results, expected around March 2027, would be the first audited test of sustained profitability.
European regulation is a potential tailwind. ProBiotix argues that possible EU restrictions on Monacolin K, the active compound in red yeast rice, could push more than 40 European brands in an estimated €130m market towards alternatives, and it puts complete substitution at up to €26m a year, although this remains a projection rather than booked business.
The prediabetes clinical programme, planned to involve more than 200 participants over three years, could widen LPLDL's positioning into metabolic health, while the YourBiotixMH range had 27 open projects at the time of the FY25 results. In the United States, management has repositioned its strategy for 2027, including localising Manufacturing to mitigate trade uncertainty.
Risks investors should watch
Customer concentration is the most obvious risk. One customer accounted for £1.014m, or 49.2%, of H1 2026 revenue, having represented 51.2% a year earlier. Any change in that relationship would materially alter the picture.
Profitability is new and slim. A £79,000 operating profit on £2.06m of revenue leaves little buffer if sales slip or costs rise. The company has no Debt but only £1.24m of cash; while it describes itself as fully funded, a downturn or a larger clinical programme could revive the need for dilutive share issuance.
US trade policy is a concern management has itself flagged. Governance history also merits attention: in late 2024 the company faced a requisitioned general meeting during a period of public exchanges with OptiBiotix, and in February 2026 the board attributed a share-price fall to investor confusion with SkinBioTherapeutics, another OptiBiotix spin-out. Aquis-quoted microcaps typically have limited liquidity, so price moves can be sharp.
Outlook
ProBiotix Health (AQSE:PBX) enters the second half of 2026 with revenue up 53%, gross margin above 60%, a half-year profit and a cash balance that held steady without fundraising. Distribution deals in Europe and Asia, the potential regulatory shift away from red yeast rice and the prediabetes study give it several avenues for growth.
The reasons for caution are just as concrete: nearly half of revenue rests with one customer, the profit margin is thin and Liquidity is limited. Investors will want the Q3 trading update to confirm the guided second-half acceleration, evidence that the customer base is broadening, and clarity on whether the EU's approach to Monacolin K turns a projected opportunity into orders.






Please wait processing your request...